Disease · MONDO_0001684
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Liprotamase vs Porcine (Pig) PERT: deaths from any cause | 0 of 65 | 0 of 63 | 128 | NCT02279498 | Trial comparisons |
| Liprotamase vs Porcine (Pig) PERT: serious adverse events | 7 of 65 | 6 of 63 | 128 | NCT02279498 | Trial comparisons |
| Creon® vs Creon N: serious adverse events | 0 of 39 | 0 of 41 | 80 | NCT02137382 | Trial comparisons |
| MS1819 vs PERT: deaths from any cause | 0 of 40 | 0 of 38 | 78 | NCT03746483 | Trial comparisons |
| MS1819 vs PERT: serious adverse events | 0 of 40 | 0 of 38 | 78 | NCT03746483 | Trial comparisons |
| EUR-1008 (APT-1008) vs Placebo: serious adverse events | 2 of 34 | 0 of 32 | 66 | NCT00297167 | Trial comparisons |
| Pancrelipase vs Placebo: serious adverse events | 0 of 32 | 0 of 31 | 63 | NCT00510484 | Trial comparisons |
| Viokase® vs Placebo: serious adverse events | 2 of 30 | 0 of 20 | 50 | NCT00559364 | Trial comparisons |
| PANCREASE MT vs Placebo: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT00662675 | Trial comparisons |
| Pancrelipase vs Placebo: serious adverse events | 0 of 17 | 0 of 16 | 33 | NCT00690820 | Trial comparisons |
| Pancrelipase vs Placebo: deaths from any cause | 0 of 8 | 0 of 8 | 16 | NCT02985801 | Trial comparisons |
| Pancrelipase vs Placebo: serious adverse events | 0 of 8 | 0 of 8 | 16 | NCT02985801 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001684/comparisons